An injection pen of Zepbound, Eli Lilly’s weight loss drug, is displayed in New York City on Dec. 11, 2023. Brendan McDermid | Reuters Companies are increasing access to new …
The meteoric rise of weight loss drugs means consumers’ nutritional needs are “shifting” which provides new opportunities for food companies, Nestle CEO Mark Schneider told CNBC. Investors were initially concerned …
A major exchange-traded fund provider is going deep on two popular plays: megacap tech and weight loss drug stocks. In health care, Roundhill Investments is getting ready to launch a …
Sima Sistani, CEO, WW International, August 16, 2023. Scott Mlyn | CNBC Weight Watchers CEO Sima Sistani has sent an internal memo to employees attempting to reassure them that the …
An injection pen of Zepbound, Eli Lilly’s weight loss drug, is displayed in New York City, U.S., December 11, 2023. Brendan Mcdermid | Reuters For all of the promise associated …
Two experts see major challenges facing the adoption of new obesity drugs. Dr. Kavita Patel, a physician and NBC News medical contributor, believes fresh data from Novo Nordisk on Ozempic’s …